DMAC Stock Forecast: DiaMedica Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$8.27
+3.12% on the day

The 5 Wall Street analysts covering DiaMedica Therapeutics, Inc. hold a median 12-month price target of $14 — +69.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 55 of 100 as at 21 Nov 2026 — in the upper half.

Market cap
$432.7M
Ticker Nerd rank
55/ 100
Median analyst target
$14
Analysts covering
5
Revenue$0.0
Operating income−$10.5M
Net income−$10.1M
Free cash flow−$8.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−5.9%
1M
−4.6%
YTD
+3.9%
1Y
+14.5%
From 52W high
−23.2%
From 52W low
+55.2%
$5
$11
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores DiaMedica Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
55/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
83
Accruals
81
Volatility
77
Value
77
Issuance
45
Growth
37
Revisions
27
Quality
23

Momentum (83): The shares have been drifting up relative to others.

Quality (23): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

DMAC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on DMAC, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15$20$25Jan 26Apr 26Jul 26Oct 26DMACHigh $25Median $14Low $12

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
5
Buy
0
Hold
0
Sell
$12
Low
$14
Median
$25
High

The green dot is the last close — the median target sits +69.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
11 Aug 2026HC Wainwright & Co.ReiteratesBuy$12
14 Nov 2025Cantor FitzgeraldInitiatesOverweight$25
15 Aug 2025HC Wainwright & Co.ReiteratesBuy—
18 July 2025Craig-HallumMaintainsBuy—
18 July 2025HC Wainwright & Co.MaintainsBuy—
18 July 2025Lake StreetMaintainsBuy—
29 May 2025HC Wainwright & Co.ReiteratesBuy—
19 Mar 2025HC Wainwright & Co.MaintainsBuy—
15 Nov 2024HC Wainwright & Co.ReiteratesBuy—
10 Oct 2024HC Wainwright & Co.ReiteratesBuy—
7 Oct 2024HC Wainwright & Co.InitiatesBuy—
16 Aug 2024OppenheimerReiteratesOutperform—
24 Apr 2024Craig-HallumAssumesBuy$8.00
21 Mar 2024Craig-HallumMaintainsBuy—
21 Mar 2024OppenheimerReiteratesOutperform—
22 June 2023OppenheimerUpgradeOutperform—
7 July 2022Craig-HallumMaintainsBuy—
7 July 2022Lake StreetMaintainsBuy—
7 July 2022OppenheimerDowngradePerform—
30 June 2021Roth CapitalMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for DMAC.

Market Radar

This page is one stock. Monday covers all of them.

DMAC appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

DMAC vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, DiaMedica Therapeutics, Inc. returned +14.5% against +6.9% for the S&P 500, dividends included.

DMAC vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160Jan 26Apr 26Jul 26Oct 26DMACS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

DMAC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
3
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
15.2×

Cheaper than 5% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−100.2%

Higher than 13% of US stocks

Return on assets
−56.1%

Higher than 7% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • DiaMedica Therapeutics, Inc. has a market value of $432.7M and an enterprise value of $398.0M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$37.5M.

  • Free cash flow in the twelve months to 30 June 2026: −$31.5M.

  • Shares outstanding: 53.9M.

  • DiaMedica Therapeutics, Inc. employs 35 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

DMAC and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
DMACDiaMedica Therapeutics, Inc.$432.7M55
BLSMBlossomhill Therapeutics, Inc.$444.6M1
PRTAProthena Corp. Plc$442.5M90
STTKShattuck Labs, Inc.$447.6M61
ASMBAssembly Biosciences, Inc.$439.7M79
CTMXCytomX Therapeutics, Inc.$438.8M46
MDXGMiMedx Group, Inc.$453.1M67

Take a look at DMAC’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own DiaMedica Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about DMAC

What is the DMAC stock price forecast for 2026-2027?

The 5 Wall Street analysts covering DiaMedica Therapeutics, Inc. have a median 12-month price target of $14, with estimates ranging from $12 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is DMAC stock a buy right now?

Of the 5 analysts covering DiaMedica Therapeutics, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks DiaMedica Therapeutics, Inc. 55 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank DMAC?

As at 21 Nov 2026, DiaMedica Therapeutics, Inc. ranks 55 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Momentum (83 of 100).

Will DMAC stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +69.3% from the last close, and Ticker Nerd's factor model ranks DiaMedica Therapeutics, Inc. 55 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the DMAC stock forecast for 2030?

No analyst covering DiaMedica Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DMAC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $25 over the next 12 months.

How has DMAC stock performed over the past year?

DiaMedica Therapeutics, Inc. returned +14.5% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does DiaMedica Therapeutics, Inc. do?

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for serious vascular and ischemic diseases. Its current pipeline is centered on DM199, a recombinant form of human tissue kallikrein-1 being studied for acute ischemic stroke, preeclampsia, fetal growth restriction, and other conditions linked to impaired blood flow.

Company

About DiaMedica Therapeutics, Inc.

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for serious vascular and ischemic diseases. Its current pipeline is centered on DM199, a recombinant form of human tissue kallikrein-1 being studied for acute ischemic stroke, preeclampsia, fetal growth restriction, and other conditions linked to impaired blood flow. The company also advances DM300, a recombinant human ulinastatin candidate in preclinical development for inflammatory disorders. DiaMedica Therapeutics serves the neuroscience, women’s health, renal, and inflammatory disease areas through therapies designed to address significant unmet medical needs. Headquartered in Minneapolis, Minnesota, DiaMedica Therapeutics Inc. operates as a specialized biotech platform focused on recombinant protein-based drug development.

CEO Mr. Dietrich John Pauls MBA · 35 employees · United States · https://www.diamedica.com